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Abstract
Neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease
(PD) are characterized by progressive neuronal loss and pathological accumulation of some
proteins. Developing new biomarkers for both diseases is highly important for the early diag-
nosis and possible development of neuro-protective strategies. Serum antibodies (AIAs)
against neuronal proteins are potential biomarkers for AD and PD that may be formed in
response to their release into systemic circulation after brain damage. In the present study,
two AIAs (tubulin and tau) were measured in sera of patients of PD and AD, compared to
healthy controls. Results showed that both antibodies were elevated in patients with PD and
AD compared to match controls. Curiously, the profile of elevation of antibodies was differ-
ent in both diseases. In PD cases, tubulin and tau AIAs levels were similar. On the other
hand, AD patients showed more elevation of tau AIAs compared to tubulin. Our current
results suggested that AIAs panel could be able to identify cases with neuro-degeneration
when compared with healthy subjects. More interestingly, it is possible to differentiate
between PD and AD cases through identifying specific AIAs profile for each neurodegenera-
tive states.
Introduction
Parkinson’s disease (PD) and Alzheimer’s disease (AD) are the commonest neurodegenerative
diseases with late diagnosis [1,2,3] and hence their devastating prognosis [1,2]. Clinical
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diagnosis of PD depends on several motor manifestations, which occur 10–20 years after the
beginning of neuro-degeneration and loss of over 60% of dopaminergic neurons [4]. Similarly,
pathological changes of AD develop over many years before manifestations of subtle cognitive
impairment [5]. This gives a very low chance for development of effective treatment. Thus the
discovery of early diagnostic biomarkers could be able to pave the way for discovering a new
and effective neuro-protective strategies for these diseases [6].
As in most neurodegenerative states, PD is accompanied by neuronal damage in certain
brain areas, namely substantia nigra and striatal dopaminergic system [7]. Likewise, AD is
associated with neuronal loss that starts many years before the appearance of clinical manifes-
tations [8]. Neuronal damage leads to the release of some neural proteins that pass through the
damaged blood-brain barrier (BBB) and enter the systemic circulation. As these proteins are
normally hidden from the body’s immune system, they will be received by humoral immunity
as new antigens warranting the formation of autoantibodies (AIAs) against them. Therefore,
these formed AIAs could be used as diagnostic peripheral biomarkers in several neurodegener-
ative diseases including PD and AD [9].
In the recent few years, there has been a growing interest and proof showing that humoral
response may be involved in the pathogenesis of neurodegenerative diseases. Consequently,
serum AIAs antibodies directed against different self-antigens may play a role in the patho-
physiology of different neurodegenerative diseases [10–13]. Although several hypotheses have
proposed the elevation of AIAs in patients’ sera, little attention has been paid for their use as
biomarkers for diagnosis of PD [14–16]. The choice of AIAs panel depends on their role in the
pathogenesis of a disease, hence the possibility of damage and release during the course of
such disease [17,18]. One class of neuronal proteins that has a strong correlation to central ner-
vous system (CNS) homeostasis and function is the microtubules group [19].
Microtubules (MTs) are polymers of α/β-tubulin heterodimers [20]. MTs are involved in
many cellular functions e.g. cell division and cellular transport, through interaction with the
so-called MT-associated proteins [21]. Therefore, it was hypothesized that neurons express
their distinctive morphology through support by intra-neuronal MT-dependent networks
[22]. It is noteworthy to mention that one important step in axonal degeneration is the dying-
back phenomenon [23]. In this detrimental process, axonal degeneration begins distally back
to the cell body in what is called axon retraction model [23]. The later seems to be initiated by
disruption of neural cytoskeleton through defective MTs as reported previously [24,25] and
confirmed by findings in several neurodegenerative conditions[26]. Based on the aforemen-
tioned notions, defects in tubulin (e.g. genetic abnormalities in its genes) could lead to several
neurological states [27–29]. It is interesting to highlight that the dying back phenomenon plays
an important role in PD neuronal death [30]. It was therefore hypothesized that there is a
strong correlation between MTs and PD related protein such as leucine-rich repeat kinase 2
(LRRK2), synuclein, and Parkin [31,32].
Turning to another class of cytoskeletal proteins that has been deeply involved in regulation
of MTs function, which is the Microtubule Associated Proteins (MAPs). Quite recently, con-
siderable attention has been paid to study the role of Tau in neuro-degeneration [33]. Tau was
reported to play a vital role in AD pathogenesis as well as in a group of other disorders that
share tau protein abnormalities, hence, named collectively “tauopathies” [34, 35]. More inter-
estingly, tau was proved to be involved in PD as well [36]. In the present study, we explore the
possibility of using a panel of AIAs against two MTs related proteins; Tubulin (TUB) and
Microtubule-Associated Protein Tau (TAU), as potential peripheral biomarkers for diagnosis
of PD and AD.
AIAs for PD and AD
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Materials and methods
Patients recruitment
Twenty-six PD; 15 AD and 10 healthy subjects (as controls) were recruited for the current
cross-sectional study from Ain Shams University, Movement Disorders Clinic and Okasha
Institute of Psychiatry, Egypt. Subjects were exposed to comprehensive medical examination
to confirm the staging and scoring of each disease. Controls were examined as well to exclude
the possibility of any other neurodegenerative disorders.
Recruited PD patients were diagnosed according to the British Parkinson ‘s Disease Society
Brain Bank criteria [37]. Staging of PD was done using the Unified Parkinson’s Disease Rating
Scale (UPDRS), Hoehn and Yahr scale (H&Y), and Schwab and England scales (S & E) in
“medication Off” and “On” states. Patients’ exclusion criteria included presence of dementia,
atypical or secondary parkinsonism. Vis-à-vis AD Patients were diagnosed according to the
NINCDS-ADRDA and DSM-IV criteria for dementia [38] and assessed using the Arabic ver-
sion of the Montreal Cognitive Assessment (MoCA) test [39,40]
The study was approved by the Institutional Review Board (IRB) of Mansoura School of
Medicine, and Ethical Committee of Faculty of Medicine, Ain Shams University. All partici-
pants signed informed consent prior to the enrolment in our study.
Blood samples were withdrawn from both control and case into anticoagulant-free tubes,
then, sera were obtained by centrifugation of blood at 3000 RPM for 20 min at 4 C˚ then ali-
quoted and stored at -20 C˚ (for no more than 1 week) prior to their transfer to the Medical
Experimental Research Center (MERC) of Mansoura University and stored at—80 0C.
Autoantibodies estimation
All antibodies have been assayed using a MyBioSourceTM enzyme-linked immunosorbent
assay (ELISA) kits (San Diego, CA, USA). Serum concentrations of Microtubule-associated
Protein Tau antibody (anti-MAPT) and Tubulin Alpha 1B Chain Antibody (TUBA1BA) were
determined by quantitative sandwich ELISA (Cat. No. MBS9310801, MBS108941, respec-
tively). Testing steps have been carried out according to the manufacturer’s provided proto-
cols. The absorbance was read using an automatic microplate reader (Optica, Mikura Ltd, UK)
at 450 nm. The sensitivity of the assay was 0.1 ng/ml.
Data analysis
Data analysis was performed, using Statistical Package for Social Science (SPSS 20), to identify
the ability of autoantibodies to separate cases (PD and AD) from controls. Continuous variables
were compared using one-way ANOVA followed by post hoc analysis using the Bonferroni test.
To differentiate between controls, PD cases and AD cases, we performed the following anal-
yses methods: individual correlation value for biomarkers, histograms and distribution curves.
Correlations between serum levels of AIAs and clinical data of the studied groups using Pear-
son’s (for parametric data) and Spearman’s (for non-parametric data) coefficients tests.
Results
Demographic and clinical data of cases
Mean age of PD patients was 52.92 ± 11.98 years old (range 23–69), while the mean age of
patients with AD was 71.88 ± 7.0 years old (range 61–81). Males were 50% of recruited subjects
of both diseases. Table 1 summarizes demographic, clinical and serum autoantibodies data for
both patients and control.
AIAs for PD and AD
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Autoantibodies levels
The results of both tested AIAs showed statistically significant elevation in both diseases (PD
and AD) compared to controls (p< 0.001) (S1 Table). Post-Hoc analysis showed non-signifi-
cant differences between PD and AD regarding serum AIAs of Tau (p = 0.069) and Tubulin
(p = 1.00).
Correlation values
From the data analysis, we could differentiate patients from controls where tubulin has the
highest correlation to the cases (r = 0.629 for tubulin and r = 0.327 for tau).
Tubulin AIAs level was a true differential factor between patients and control, wherein con-
trols tubulin AIAs were not significant. In other words, when tubulin AIAs were detected in
sera then it was an indication of a neurodegenerative disease as seen in “Fig 1”. Tau AIAs also
showed the ability to differentiate patients from controls as seen in “Fig 1”. Serum Tau AIAs
were significantly correlated to duration of illness (r = 0.563, p = 0.029) in patients with AD,
and a trend for significance with MOCA scores (r = -0.490, p = 0.061), while tubulin serum
AIAs did not show significant correlation. MOCA was correlated to the age of patients
(r = 0.916, p = 0.013), and age of onset (r = -0.519, p = 0.039). Both AIAs did not show a signif-
icant correlation with UPDRS III off, H & Y off, and S& E off scales among PD patients.
Histograms
From the histograms “Fig 2”, we can easily separate patients from control using the biomark-
ers. Regarding differentiation between different diseases, most of PD patients showed a similar
elevation for tubulin and tau AIAs levels. On the other hand, AD patients showed higher val-
ues of Tau AIAs compared to tubulin AIAs.
Level distribution curves
Distribution curves showed possible classification of studied samples into three distinctive
groups (based on the identification of peaks representing clusters of cases) as follows:
Table 1. Demographic, clinical and serum autoantibodies of patients with PD and AD diseases.
PD Patients; Mean ± SD (n = 26) AD patients; Mean ± SD (n = 15) Controls; Mean ± SD (n = 10)
Age (years) 52.92 ± 11.98 (range 23–69) 71.88 ± 7.0 (range 61–81) 61.22 ± 5.4 (range 44–72)
DOI (years) 5.48 ± 3.03 (1–10) 4.47 ± 2.81 (1–9) ——————
AOO 47.44 ± 11.38 (22–63) 67.41 ± 6.19 (59–75) ——————
MOCA —————— 16.13±5.20 ——————
H&Y off 3.33±1.19 —————— ——————
H&Y on 1.54±1.15 —————— ——————
S&E OFF 45.00±26.04 —————— ——————
S&E ON 80.42±18.99 —————— ——————
UPDRS I off 5.42±2.60 —————— ——————
UPDRS II off 24.74±12.17 —————— ——————
UPDRS III off 50.79±17.42 —————— ——————
TUB AIAs 4.04 ± 0.30 3,92 ± 0.26 0.228 ± 0.50
Tau AIAs 3.93 ± 0.28 7.72 ± 6.20 0.45 ± 0.50
SD, standard deviation; H&Y, Hoehn and Yahr Scale; S&E, Schwab and England Scale, UPDRS, Unified Parkinson’s Disease Rating Scale, AIAs; autoantibodies
 = P < 0.001 compared to control.
https://doi.org/10.1371/journal.pone.0196436.t001
AIAs for PD and AD
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“Fig 3A” illustrates the distribution curve for tubulin AIAs. As can be seen from this figure,
there are 3 groups: group 1: control—from 1 to 1.2; group 2 –from 1.2 to 6; and group 3 –from
6 upwards. Combining data from the curve to previous histogram graphs, group 2 should be
AD and group 3 should be PD.
As shown in “Fig 3B”, tau distribution curve yielded 3 groups: group 1 –control—from 0 to
1.2; group 2 –from 1.2 to 8; and group 3 –from 8 upwards. Here AD range exceeds the curve
and from previous histogram graphs, group 2 should be PD and group 3 should be AD.
Plotting data from both AIAs “Fig 3C” showed possible differentiation between cases and
controls. Moreover, the curve shows the possibility of identifying different distribution profiles
specific for PD and AD. (Tubulin in blue and Tau in red).
Discussion
This paper is a modest contribution to the ongoing discussion on peripheral biomarkers for
diagnosis of PD and AD. In the present report, we have evaluated a panel of two autoantibod-
ies against MTs related proteins (Tubulin and Tau) as peripheral biomarkers for diagnosis of
Fig 1. Serum autoantibodies titers of Tubulin (A) and Tau (B) in investigated groups. Higher levels of both AIAs were higher in patients of PD and AD compared to
controls.
https://doi.org/10.1371/journal.pone.0196436.g001
AIAs for PD and AD
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PD and AD. Our results showed that this small panel could differentiate patients from
matched controls as evidenced by statistically significant elevation in the two autoantibodies
levels among selected patients. Likewise, the panel showed a specific profile for each disease,
hence, its benefit in differentiation between PD and AD.
There is a necessity for developing biomarkers that can help in early diagnosis of neurode-
generative diseases, including PD and AD [41]. Since conventional diagnostic tools could not
identify in early stages, it is essential to use novel methods [6]. One promising approach is
detecting serum autoantibodies against neural proteins involved in the pathogenesis of these
disorders [42]. Quantification of these autoantibodies would be an easy, accessible and cost-
efficient biomarker for neurodegenerative diseases [43]. The ideal biomarker should be sensi-
tive and specific that it should identify every case compared to controls; meanwhile, it should
also differentiate between similar diseases [44].
Fig 2. Histograms showing levels of autoantibodies in different groups (mean ± SEM). Tubulin AIAs show a
significant elevation in PD and AD cases compared to control. On the other hands, Tau was elevated in both diseases
with higher elevation in AD.
https://doi.org/10.1371/journal.pone.0196436.g002
Fig 3. Distribution curves of AIAs against tubulin (3A), tau (3B) and the combination of tubulin and tau (3C) in
different groups. Curves showed possible differentiation between cases and controls (3A and 3B) and the possibility of
identifying profiles specific for PD and AD (Tubulin in blue and Tau in red) (3C).
https://doi.org/10.1371/journal.pone.0196436.g003
AIAs for PD and AD
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A challenge in choosing autoantibodies is to identify certain neural proteins that play
important role in brain functions and affected in neurodegenerative diseases [45]. Our paper
presents an innovated view of the two neural proteins related to microtubules that are deeply
involved in the maintenance of cell integrity and function in the brain. Tubulin is the main
protein in MTs system [21], as such, it is predicted that in cases of neural damage, tubulin will
be affected. More important, tubulin has been proved to be involved in degeneration processes
in PD and was linked to PD inducing toxins and related proteins [30–32].
We have addressed not only Tubulin but also Tau. The latter is an associated protein with
MTs, hence it compliments the function to tubulin [36] though being involved in many neuro-
degenerative diseases beginning from AD, tauopathy group of diseases and even PD [35]. This
suggests different profiling of Tau compared to tubulin, which would serve for differentiating
between different diseases when using both AIAs.
In this report, tubulin was elevated in both diseases (PD and AD), which was anticipated
based on the role of MTs in the stabilization of axonal cytoskeleton and neuronal connections
[46]. Carletti et al. reported that gluta-thionylation of microtubules (e.g. tubulin) is the initia-
tory step for oxidative stress-induced damage of the neuronal cytoskeleton, hence, the dying
back pattern of axonal degeneration [47]. Niwa et al confirmed the same later where they
showed severe neuronal damage in cases of tubulin mutations [48].
The second estimated AIA, (tau), was elevated in both diseases, however, the higher values
of tau AIAs were in AD cases compared to PD, which is justifiable by the pivotal role played by
tau in AD pathogenesis [33]. More recently, tau levels showed to be high in CSF and sera of
AD patients [49–50]. Additionally, we found that serum tau AIA was related to disease dura-
tion and MOCA scores (trend for significance) in AD patients. This is in line with earlier stud-
ies reporting a significant correlation of serum tau AIAs with cognitive functions [50–52]. The
elevation of tau autoantibodies in PD patients has also been reported before [45], which may
shed light on the plausible role of tau proteins in PD pathogenesis.
It is important to notice that despite the reported non-significant levels of AIAs between
AD and PD, both diseases exerted different profiles, which could serve as a differentiation tool
between them. To our knowledge, this the first study to report the qualitative changes between
levels of AIAs. As can be seen in histograms, PD pattern showed a similar elevation in both
AIAs, whereas, AD showed a higher elevation in tau AIAs compared to tubulin (although both
AIAs were significantly higher than control). It is noteworthy that using distribution curves in
biomarkers study is more suitable since the arithmetic mean is not a robust statistic tool to be
applied for distribution studies, but is more suitable for deriving central tendency. This is
mainly due to the fact that it could be affected by the variations of the values in the sample
(either too small or too large). Distribution curves in our case showed a more differentiating
pattern for cases and each disease.
The present findings of increased IgG against tubulin and tau in AD and PD patients show
that both proteins could be involved in the pathogenesis of these diseases. A possible interpre-
tation is that these AIAs represent a “stable signature” of neuronal damage in PD and AD [9].
On the other hand, the increase in AIAs—specifically against tubulin and tau could be
explained by abnormal stimulation of immune system in the course of diseases [10] or a coex-
istence of immune-mediated polyneuropathy and neuro-degenerative disorders (PD and AD
in our current work) [53]. It is claimed that combination of previous roles may be played by
AIAs: earlier they are formed as a result of released proteins into systemic circulation through
the pathway of neurodegenerative process, later, these AIAs begin to attack brain tissues lead-
ing to more neural damage [9].
Since AIAs represent an immunological memory of damaged proteins, they could be vali-
dated as "biomarkers of effect/injury" [54]. A question that could be raised here, is the value of
AIAs for PD and AD
PLOS ONE | https://doi.org/10.1371/journal.pone.0196436 May 9, 2018 7 / 11
such biomarkers for a clinician seeking early diagnosis, and when could they be applied. The
answer to this question comes from a better understanding of most neurodegenerative disor-
ders’ pathogenesis, where environmental exposure to risk factors interact actively with genetics
to develop most of these disorders e.g. PD [55]. Since the exposure to environmental agents
takes a long time until developing overt damage that can be clinically manifested, a validated
biomarker of injury will be very useful as a detector of early exposure in the high-risk popula-
tion. It is important to notice that the threshold of damage -needed to elicit an immune
response, hence, the formation of AIAs- is much lower than the intensity of neuronal loss
leading to overt clinical symptoms of the disease [9]. This may be the motive beyond the rec-
ommendations issued by Alzheimer’s Association and the Alzheimer’s Drug Discovery Foun-
dation in 2012 advocating the need for peripheral, non-invasive blood-based biomarker that
can diagnose the disease earlier than clinical signs [56]. We believe that AIAs could detect ear-
lier brain damages years before clinical manifestations.
Conclusion
To conclude, our panel -composed of two AIAs- was able to diagnose PD and AD (i.e. differen-
tiating cases from controls). In addition, profiling different diseases seem possible. The profile
of elevated AIAs in PD was different from AD with a possibility of individualization, hence
specificity in the diagnosis of various neurodegenerative disorders. Needless to say, the main
limitation of the current report is the small number of studied cases. We believe that recruiting
a larger number of cases will, certainly, confirm our data. Nevertheless, our findings present the
first report on using tubulin and tau AIAs as peripheral biomarkers for diagnosis of PD or AD.
Supporting information
S1 Table. Table showing individual AIAs levels in patients and controls. Dataset supporting
the individual cases and controls values were uploaded to the Journal submission system.
(XLSX)
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